by Injectable drugs are vital medicines administered directly into a patient’s body, bypassing the gastrointestinal tract. They offer advantages like rapid therapeutic effects, precise dosing, and administration of drugs that cannot be delivered orally. They are widely used in cases of emergency medical care, anesthesia, cancer chemotherapy and other chronic conditions. Brazil has a fast-growing market for injectable drugs due to factors such as rising healthcare costs, increasing prevalence of chronic diseases, growing elderly population and advancements in biologics and biosimilars. Hospitals and ambulatory care settings heavily rely on these medications due to their speed and precision during medical procedures.
The global Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings is estimated to be valued at US$ 9353.45 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the Brazil injectable drugs market is the growing adoption of self-injection devices. Self-administered injectable drugs allow for convenient home treatment of chronic diseases. This reduces visits to hospitals and clinics, saving healthcare costs. Major pharmaceutical companies are focusing on development of user-friendly self-injection technologies like pre-filled syringes and wearable/patch injectors. Biologics are also an emerging area, with many pipeline drugs in development for conditions like cancer, autoimmune disorders and cardiovascular diseases. Their uptake is driving market growth in Brazil. Advancements in drug delivery technologies continue to increase preference for injectable formulations over tablets and capsules.
Porter’s Analysis
Threat of new entrants: The Brazil injectable drugs market is consolidated with the presence of established players. New entrants need significant capital to setup production and R&D facilities which poses barrier.
Bargaining power of buyers: Large number of hospitals and government purchasing power increases the bargaining power of buyers. Buyers can negotiate for volume discounts and demand new drugs.
Bargaining power of suppliers: The presence of many drug manufacturers limits the bargaining power of suppliers of raw materials and components.
Threat of new substitutes: There exists a low threat from alternative delivery forms like oral drugs due to safety, efficacy and convenience of injectable drugs.
Competitive rivalry: The market witnesses high competition due to presence of both international and domestic players. Players compete on basis of portfolio, quality, pricing and services.
Key Takeaways
The Brazil Injectable Drugs Market Size for hospitals & ambulatory settings is expected to witness high growth over the forecast period supported by growing healthcare expenditure, aging population and increasing prevalence of chronic diseases. The global Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings is estimated to be valued at US$ 9353.45 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.
Regional analysis: The southeast region dominates the market with states like Sao Paulo and Rio de Janeiro accounting for majority share supported by manufacturing clusters and availability of healthcare infrastructure. The northeast region is expected to witness fastest growth during the forecast period.
Key players: Key players operating in the Brazil injectable drugs market are Amcor Limited, Bemis Company, Sealed Air Corporation, Berry Plastics Group, Inc., Mondi Group, Sonoco Products Co., Huhtamäki Oyj, Constantia Flexibles Gmbh, Ampac Holdings, Llc, Bischof + KleinInternational, Wipak Group, AR Packaging, Goglio Group, Schur Flexibles, Clondalkin Group, Flair Flexible Packaging Solution Cellpack Packaging, and Südpack Verpackungen. Players focus on new drug launches, expansions and partnerships with hospitals to strengthen presence.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
